Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy
Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy
复制标题
选择苏糖核酸适体阻断PD-1/PD-L1相互作用用于癌症免疫治疗
DOI：
10.1039/d0cc06032a
复制
发表时间：
2020-12-04
影响因子：
4.9
通讯作者：
Yu, Hanyang
中科院分区：
文献类型：
--
作者：
Li, Xintong;Li, Zhe;Yu, Hanyang
在体外选择苏糖核酸（TNA）适体以结合PD-L1蛋白并抑制其与PD-1的相互作用。这些生物学稳定的TNA适体以纳摩尔亲和力结合靶蛋白，并在体外有效阻断PD-1/PD-L1相互作用。在注射到结肠癌异种移植小鼠模型中后，TNA适体N5特异性地积聚在肿瘤部位，并显著抑制体内肿瘤生长。
Threose nucleic acid (TNA) aptamers were selected in vitro to bind PD-L1 protein and inhibit its interaction with PD-1. These biologically stable TNA aptamers bound target proteins with nanomolar affinities, and effectively blocked PD-1/PD-L1 interaction in vitro. After injection into a colon cancer xenograft mouse model, the TNA aptamer N5 was specifically accumulated at the tumour site, and significantly inhibited tumour growth in vivo.